Pharma BD Deal Intelligence

AstraZeneca PLC / Fusion Pharmaceuticals Inc.

2024 · Acquisition/Merger · $2.4B · Complete

Announcement Sentiment

100

Strongly positive

Outcome Score

Largely worked — most objectives met.

AstraZeneca acquired Fusion Pharmaceuticals for up to approximately $2.4 billion ($21.00 per share upfront plus $3.00 per share contingent value right) in an all-cash arrangement, gaining next-generation actinium-225-based radioconjugate therapeutics and radiopharmaceutical manufacturing capabilities.

Key facts

Announced Mar 19, 2024
Closed Jun 04, 2024
Deal value $2.4B
Deal type Acquisition/Merger
Therapeutic area Oncology
Indications Metastatic Castration-Resistant Prostate Cancer, Solid Tumors
Key assets FPI-2265, Actinium-225 radioconjugate platform, Radiopharmaceutical manufacturing and Ac-225 supply chain
Mechanism Actinium-225-based targeted alpha therapy (radioconjugate)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals